Valiant Organics Ltd
BSE:540145

Watchlist Manager
Valiant Organics Ltd Logo
Valiant Organics Ltd
BSE:540145
Watchlist
Price: 241.45 INR -2.07%
Market Cap: ₹6.7B

Valiant Organics Ltd
Investor Relations

Valiant Organics Ltd. engages in the pharmaceutical business. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2016-10-14. The firm provides a range of products, including Agro Chemicals, Dyes, Pigments, Pharmaceutical, Cosmetics, Specialty Chemicals, Polymer and Veterinary products. The firm process a range of chemicals, including Chlorination, Ammonolysis, Hydrogenation, N-Alkylation, Acetylation, Sulphonation and Condensation. Its Chlorination chemical includes Ortho Chloro Phenol (OCP), Para Chloro Phenol (PCP) and di-chlorophenols, namely, 2,4 Di-chlorophenol and 2,6 Di-chlorophenol. The firm's Hydrogenation chemical includes Ortho Anisidine, Para Anisidine, Meta Chloro Aniline, Para Fluoro Aniline (PFA), 4-Fluoro-N-isopropylaniline, Para Amino Phenol and Ortho Amino Phenol. The firm also exports its products to Asia, Europe, and the United States. The firm manufactures products as per the specific requirements of its customers.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q3 2024
Call Date
Feb 15, 2024
AI Summary
Q3 2024

Revenue Decline: Valiant Organics reported a 22% year-on-year drop in Q3 revenue, driven by a 13% fall in volumes and 9% price reduction amid industry-wide demand and pricing pressures.

Net Loss: The company posted a net loss of INR 8 crores for the quarter, reflecting the challenging market environment and margin compression.

Margins Under Pressure: EBITDA margin fell to 2.69%, significantly down from historical levels due to lower sales prices and continued Chinese dumping.

FY25 Outlook: Management expects FY25 to be a better year, targeting revenue between INR 900–1,000 crores, assuming market demand recovers and new products ramp up.

Capacity Utilization & Growth: PAP plant running below full capacity due to limited customer approvals; further volume ramp-up depends on onboarding new clients.

No Major CapEx: No large capital expenditure planned for FY25 beyond normal maintenance, as management waits for demand to stabilize.

China Competition: Persistent Chinese dumping and subdued end-market demand (especially in Europe and textiles) remain key headwinds.

Key Financials
Revenue
INR 141 crores
EBITDA
INR 4 crores
EBITDA Margin
2.69%
Net Loss
INR 8 crores
Net Debt
INR 165 crores
PAP Plant Utilization
600–700 metric tons per month
Maintenance CapEx
INR 30–40 crores
Other Earnings Calls

Management

Mr. Sathiababu Krishnan Kallada
MD & Executive Director
No Bio Available
Mr. Mahek Manoj Chheda
CFO & Whole-Time Director
No Bio Available
Mr. Siddharth Dinesh Shah
Executive Director
No Bio Available
Mr. Kaustubh Kulkarni
Company Secretary & Compliance Officer
No Bio Available

Contacts

Address
MAHARASHTRA
Mumbai
109, Udyog Kshetra, 1st Floor, Mulund Goregaon Link Road, Mulund (W)
Contacts